Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions

This publication has 25 references indexed in Scilit:

• Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
  Journal of the American College of Cardiology, 2001
• Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease
  Circulation, 1998
• Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction
  Circulation, 1998
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study
  The Lancet, 1997
• The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions
  Molecular Immunology, 1995
• Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention
  Circulation, 1995
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994
• Cumulative Meta-Analysis of Therapeutic Trials for Myocardial Infarction
  New England Journal of Medicine, 1992
• A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.
  Journal of Clinical Investigation, 1983